Lymphoma & Plasma Cell Disorders

Conference Coverage

When is denosumab an option in myeloma?

CHICAGO – ASH guideline coauthor explains the evidence behind the group’s recent guidelines on bone-modifying agents in multiple myeloma.

Pages